GRIP - The Global Regulatory Intelligence Club for Pharmacovigilance

GRIP - The Global Regulatory Intelligence Club for Pharmacovigilance

Products & Services

Information

An extensive compilation of global PV (Pharmacovigilance) regulatory documents and associated reporting rules. Documents are provided in source language with translated English version. The accompanying expedited reporting rules have been collected and analysed by Insife’s pharmacovigilance experts. The team consistently assesses and interprets changes in legislation and finds the relevant new information for GRIP members, taking that time consuming, but vital, job out of your hands. The service currently covers 160+ countries. Intelligence data are presented to you in HALOPV, providing a means for maintaining the base requirements and then being able to extend and tailor them for your own specific commitments and waivers. If you already have a subscription for HALOPV or HALOPV Enterprise Requirements Intelligence module, you are all set from a technology point of view… we will just load the requirements into your environment.
Insife39Insife is a leading provider of pharmacovigilance solutions, offering a comprehensive platform and expert consulting to help pharmaceutical and biotech companies efficiently navigate drug safety processes. With nearly 100 safety experts worldwide, Insife provides the largest Europe-based pharmacovigilance services and solutions in the industry. The company's flagship product HALOPV is an end-to-end system to manage multivigilance processes from operational to scientific tasks. Insife also offers regulatory intelligence, hosting services, and strategic consulting to deliver outstanding domain expertise across the US, Europe, and Asia. With a commitment to transforming drug safety through innovation, Insife is changing the technology landscape for pharmacovigilance worldwide. In March 2024, it was announced that Qinecsa Solutions, specialists in technology-led end-to-end pharmacovigilance solutions, had acquired Insife. The acquisition will enable Qinecsa to leverage Insife's expertise in software development and consultancy, to enhance its existing pharmacovigilance services and accelerate further innovation in the field. Together, the companies will continue to lead the industry in advancing patient safety, drug development, and regulatory compliance through AI-driven technologies and cutting-edge solutions.

Log in